Drug Search Results
More Filters [+]

Lipegfilgrastim

Alternative Names: lipegfilgrastim
Latest Update: 2023-10-02
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: G-CSF

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Chile | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | Spain | Sweden | Taiwan | Turkey | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lipegfilgrastim

Countries in Clinic: New Zealand, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Hepatitis B, Chronic|Intestinal Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-7041-83/hah

P2

Not yet recruiting

Hepatitis B, Chronic|Intestinal Diseases

None

Recent News Events